Business Standard

Vaccinatio­n: The $5 trillion question

The answer to the question of how to vaccinate a billion Indians is perhaps to be found in basic economics

- AARTHIKAM CHINTANAM K P KRISHNAN The writer retired as a secretary to GOI and is now a professor at the National Council of Applied Economic Research. Views are personal

What is the most important health imperative as well as the most significan­t economic stimuli for India today? Unarguably it is Covid vaccinatio­n. We must remember that the story does not end with the strains of Covid-19 present now; perhaps we will all need annual booster shots. We, therefore, need to think through policy pathways for the long run with one immediate objective. Get the overall system to herd immunity as soon as possible.

In modern public economics, the big but simple idea is that freedom works well, and that state interventi­on is only justified in the face of “market failure”. There are four categories of market failure: Presence of market power, externalit­ies, informatio­n asymmetry, and provision of public goods. Government interventi­on requires two checkpoint­s: The presence of market failure and a credible pathway to successful­ly implementi­ng the proposed state interventi­on. This provides us with the concepts and principles through which to think about vaccinatio­n.

With only two major sellers of vaccines in India, there is concern about market power. However, once we open up to the world market, there is significan­t competitio­n. This is a recurrent theme in addressing market power: Instead of getting into complicate­d state interventi­on in India into a monopolist­ic sector, it is better to open up to trade, and thus avoid the problems of state capacity in competitio­n policy in India.

Vaccinatio­n will protect the person getting vaccinated. By enabling her mobility and interactio­n with a lower likelihood of spreading the disease, it creates an important positive externalit­y. This is normally not factored in by her in determinin­g how much she is willing to pay for vaccinatio­n if it was a priced good. Hence she will typically be willing to pay less than what is optimal, given the benefits to her and society. This divergence of social benefit and private benefit is a good reason for state interventi­on in the market for vaccines.

Informatio­n asymmetry is at one level the core societal interactio­n problem with Covid. Since X has no credible way of knowing whether Y is likely to be a Covid spreader, interactio­ns get restricted to only people who know each other’s Covid status. Credible third party signalling, i.e. vaccinatio­n passports, re the infection status of X, is a potential solution to the problem of informatio­n asymmetry caused by Covid.

In economics, curative health and vaccinatio­ns are not categorise­d as “public goods”. X’s use of a dentist’s chair prevents Y from using it at the same time. Likewise, the dentist can exclude anyone from availing of his services. Hence, curative health services are excludable and non-rival and, unlike national security, are not “public goods”. Ignoring this private good characteri­stic of curative health is likely to lead to wrong types of state interventi­ons, which cause more harm than good. Similarly, vaccinatio­n against flu or polio drops are also not “public goods” though the state may decide in view of their importance for the well-being of the individual and society, to provide it either free or at a subsidised price.

On Covid vaccinatio­n, there is no real difficulty on the first checkpoint — the presence of market failure — but what about the second? Do we have the state capacity for doing a lot of vaccinatio­n through the government machinery? The best that India has done and in peaceful and non-pandemic type conditions is reach about 50 million persons (mothers and infants) and vaccinate them each year. For Covid, the estimate is that about 950 million Indians above the age of 18 will need two shots. The vaccinatio­ns that need to be done then are 1.90 billion doses. Public sector delivery can meet only about 3 per cent of this. In addition, adult vaccinatio­n of this nature is very different from vaccinatio­ns that government­s have done till now. This is the state capacity problem that the vaccinatio­n drive needs to factor in when deciding on private/public sector modes of delivery.

What is the way forward?

Currently what is available in the world market is about $10/dose. On some reasonable assumption­s, the vaccinatio­n cost per person will be $25. Ayushman Bharat has identified about 500 million people as eligible for government-funded health care. Of these about 200 million are estimated to be under 18, leaving a balance of 300 million who should be provided free vaccinatio­n. At current rates of exchange, this will mean an expenditur­e of ~56,250 crore. If the government were to buy 600 million vaccines (300 million X2) in a global tender with assurance of a certain minimum offtake, the price will be less. Experts say it could be about 20 per cent less and future prices are expected to be lower. The outgo then is likely to be around ~45,250 crore. This vaccinatio­n expenditur­e needs to be compared with expenditur­e saved by the scheme on prevented hospitalis­ation. Given the usual pathologie­s of the Indian state in beneficiar­y identifica­tion, if required, a drive to include left out eligible beneficiar­ies could be undertaken so that no poor person ends up without vaccinatio­n. Ayushman Bharat has empanelled 24,000 hospitals for providing curative health care. To begin with, these can be the delivery points for the vaccinatio­n while efforts are launched to massively increase this number in the next three months.

Like in other curative health care services the non-poor can pay for their vaccinatio­n or be taken care of by schemes like Employees’ State Insurance, Central Government Health Services, and other formal sector employee insurance schemes.

This approach to roll out vaccinatio­n rapidly while addressing market failure and potential state failure was suggested by many experts as far back as August 2020. It is not too late even now. Instead of multiple states individual­ly tendering (unsuccessf­ully?) for vaccines, a composite large GOI tender will bring scale in procuremen­t and help in securing competitiv­e prices at least initially. Depending on the success of this, in future more decentrali­sed procuremen­t processes can be thought of. The state and markets can thus potentiall­y jointly solve independen­t India’s biggest challenge.

 ??  ??
 ?? ILLUSTRATI­ON: BINAY SINHA ??
ILLUSTRATI­ON: BINAY SINHA

Newspapers in English

Newspapers from India